Cargando…

Clinical Outcomes and Healthcare Resource Utilization in a Real-World Population Reflecting the DAPA-CKD Trial Participants

INTRODUCTION: The DAPA-CKD trial assessed dapagliflozin in patients with chronic kidney disease (CKD) with or without type 2 diabetes (T2D). To aid interpretation of results, renal and cardiovascular outcomes plus healthcare resource utilization (HCRU) and costs were assessed in a real-world populat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Olufade, Tope, Lamerato, Lois, Sánchez, Juan José García, Jiang, Like, Huang, Joanna, Nolan, Stephen, Rangaswami, Janani
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889671/ https://www.ncbi.nlm.nih.gov/pubmed/33474707 http://dx.doi.org/10.1007/s12325-020-01609-2

Ejemplares similares

Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis
por: McEwan, Phil, et al.
Publicado: (2022)

DAPA-CKD: The Beginning of a New Era in Renal Protection
por: Cherney, David Z.I., et al.
Publicado: (2021)

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
por: Wheeler, David C, et al.
Publicado: (2020)

Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial
por: Marx, Nikolaus, et al.
Publicado: (2021)

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study
por: Beernink, Jelle M., et al.
Publicado: (2023)

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial
por: Chertow, Glenn M., et al.
Publicado: (2023)

The Real-World Utilization Pattern of Increased Utilization of Advanced Topical Adjunctive Hemostats in a Vertically Integrated Healthcare System
por: Stern, Lee, et al.
Publicado: (2017)

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
por: McAllister, Peter, et al.
Publicado: (2021)

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

Epidemiology and outcomes in patients with anemia of CKD not on dialysis from a large US healthcare system database: a retrospective observational study
por: Lamerato, Lois, et al.
Publicado: (2022)

Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
por: Waijer, Simke W., et al.
Publicado: (2022)

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
por: Heerspink, Hiddo J L, et al.
Publicado: (2021)

Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort
por: Pollock, Carol, et al.
Publicado: (2022)

Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial
por: Wheeler, David C, et al.
Publicado: (2021)

Clinical and Healthcare Utilization Outcomes of Parathyroidectomy in CKD and Dialysis Patients
por: Jones, Scott A., et al.
Publicado: (2020)

DAPA-HF trial signals the birth of ‘diabetic cardiology’ and more
por: Wagdy, Kerolos, et al.
Publicado: (2020)

The DAPA Trial in the Context of Previous Prophylactic ICD Landmark Trials
por: Haanschoten, Danielle, et al.
Publicado: (2021)

Bioimpedance in CKD: an untapped resource?
por: Mayne, Kaitlin J, et al.
Publicado: (2022)

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
por: Docherty, Kieran F, et al.
Publicado: (2020)

DAPA-HF study: Are the benefits uniform across non-diabetic subgroups
por: Pareek, Anil, et al.
Publicado: (2020)

The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context
por: McMurray, John J V, et al.
Publicado: (2020)

Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Sodium-Glucose Cotransporter-2 Inhibitors—Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials
por: Gohda, Tomohito, et al.
Publicado: (2022)

Reflections on community mental healthcare around the world
por: Skuse, David
Publicado: (2020)

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Jackson, Alice M., et al.
Publicado: (2020)

Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
por: Curtain, James P, et al.
Publicado: (2021)

Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF
por: McDowell, Kirsty, et al.
Publicado: (2022)

Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

CKD hotspots around the world: announcement
Publicado: (2014)

Application in the World of Understanding: Researchers’ Experiences of Participation in Reflective Dialogues
por: Nyholm, Linda, et al.
Publicado: (2018)

Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting
por: Braunstahl, Gert-Jan, et al.
Publicado: (2014)

Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy
por: Moccia, Marcello, et al.
Publicado: (2022)

P1059: REAL-WORLD TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION IN MYELOFIBROSIS PATIENTS WITH ANEMIA
por: Mascarenhas, John, et al.
Publicado: (2023)

Cardio-Renal-Metabolic Care Models: Toward Achieving Effective Interdisciplinary Care
por: Rangaswami, Janani, et al.
Publicado: (2020)

Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER
por: Desai, Akshay S., et al.
Publicado: (2022)

Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA‐HF
por: Adamson, Carly, et al.
Publicado: (2022)

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
por: Butt, Jawad H., et al.
Publicado: (2021)

Impact of Electronic Chronic Pain Questions on patient-reported outcomes and healthcare utilization, and attitudes toward eCPQ use among patients and physicians: prospective pragmatic study in a US general practice setting
por: Lamerato, Lois, et al.
Publicado: (2023)

Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization
por: Hubert, Dominique, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rujaho0cbip92si9mcpcck6mub